Single and Multiple Dose Asian Bridging Study

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Subjects

In brief

The purpose of this study is to evaluate the single-dose (SD) pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of 10, 40, and 80 mg E5501 followed by a selected dose for multiple dosing (MD) in healthy Japanese, Chinese, and Caucasian subjects.

Key facts

Study ID

NCT01251731

Run by

Eisai Inc.

People needed

36

Starts

2010-07-01

Last updated by the study team

2012-04-06

Who can join

Age: 20 and older, up to 45. Sex: any. Healthy volunteers: accepted.

Where it is running

• Parexel International, Early Phase Clinical Unit — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.